However, the methods of endostatin treatment differed among studies, including continuous intravenous pumping (CIV) of endostatin (7.5 mg/m2/day) over 5 days, administration of endostatin (7.5 mg/m2/day) over 4 h for 7 days at weeks 1, 3, 5, and 7 or via an endostatin intravenous drip (IV) (15 mg/day) for 14 days per 3 weeks, etc. Almost all included patients had unresectable LA-NSCLC at the time of study entry. Here, COL18A1 is linked to non-small cell lung carcinoma.